– USA, TX – Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the appointment of Amy P. Sing, M.D. to its Board of Directors, bringing the number of board members to five.
Dr. Sing, 56, currently serves as Senior Director of Medical Affairs at Genomic Health, Inc., a leading publicly held biotechnology company that assists physicians and patients in making personalized cancer treatment decisions. From 2004 to 2011, Dr. Sing worked in various leadership and research positions at Genentech, Inc. Most notably, Dr. Sing led the oversight of the Investigator Sponsored Trials (IST) program for the now approved breast cancer drug Avastin. Dr. Sing’s experience in the biotechnology sector also includes directing research teams for Seattle Genetics, Inc. and Program Leader for CellPro, Incorporated. Dr. Sing started her career in drug development at Fred Hutchinson Cancer Research Center and the University of Washington. Throughout her career, Dr. Sing has received numerous awards for her work, including from the National Cancer Institute, American Cancer Society and Stanford University. Dr. Sing holds a B.A. from Amherst College and an M.D. from Stanford University.
“I believe Amy will make an excellent addition to our Board of Directors, and I am pleased to welcome her to the team,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path. “Amy’s experience in bringing cancer treatments to market will be of tremendous benefit as Bio-Path continues to move its product pipeline through the clinic.”
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
